ORPHA:100021
Primary plasmacytoma of the bone
Publications
2
8th percentile
Trials
0
Interventional, condition-specific
Researchers
8
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
How rare: 1-9 / 1 000 000 — roughly one to nine people per million. In a city the size of Kolkata, perhaps a few dozen.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
2 matched papers (1 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPartial
None under the specific name; 31 for broader category plasmacytoma
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
2
2 papers have ever been indexed under this name. For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
2 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
1 in the last 10 years · high confidence · 8th percentile (publications denominator)
Phrase hits: 2 · MeSH hits: 0
Who's working on it?
8
Distinct author names in 2 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Aguado-Bueno B1 paper · 2024
Department of Hematology, University Hospital La Princesa, IIS-Princesa, Calle Diego de León 62, 28005 Madrid, Spain.
Papers in Europe PMC - 02Carvalho R1 paper · 2012Papers in Europe PMC
- 03Fernandes JS1 paper · 2012Papers in Europe PMC
- 04Gómez-León N1 paper · 2024
Department of Radiology, University Hospital La Princesa, IIS-Princesa, Calle Diego de León 62, 28005 Madrid, Spain.
Papers in Europe PMC - 05Kurochka S1 paper · 2012Papers in Europe PMC
- 06Lumbreras-Fernández B1 paper · 2024
Department of Radiology, University Hospital La Princesa, IIS-Princesa, Calle Diego de León 62, 28005 Madrid, Spain.
Papers in Europe PMC - 07Rocha J1 paper · 2012Papers in Europe PMC
- 08Rodríguez-Laval V1 paper · 2024
Department of Radiology, University Hospital La Princesa, IIS-Princesa, Calle Diego de León 62, 28005 Madrid, Spain.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 31 trials are registered for plasmacytoma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
high confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
31 interventional trials matched plasmacytoma, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: plasmacytoma
31
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07705074·NOT YET RECRUITING·FAPI PET Imaging - An Exploratory Study
Conditions: Thyroid Pathology · Head and Neck Cancer (H&N) · Sinonasal Tract Tumor · Sarcoidosis·Matched via name phrase
- NCT06435910·NOT YET RECRUITING·Engineered Dendritic Cell Vaccines for Multiple Myeloma
Conditions: Multiple Myeloma or Plasmacytoma·Matched via name phrase
- NCT07115667·RECRUITING·Radiation Combined With BCMA/CD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow Infiltration
Conditions: Solitary Bone Plasmacytoma · Plasmacytoma of Bone · Plasma Cell Disorders·Matched via name phrase
- NCT06429150·NOT YET RECRUITING·Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma
Conditions: Multiple Myeloma · Plasmacytoma·Matched via name phrase
- NCT06863584·RECRUITING·SBRT Plus Lenalidomide for Solitary Plasmacytoma: Phase II Trial
Conditions: Solitary Plasmacytoma·Matched via name phrase
- NCT05248633·RECRUITING·Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary Plasmacytoma
Conditions: Solitary Plasmacytoma·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 8 · after dedupe 8 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 8 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (8)
- isrctn·ISRCTN98606172·Recruiting·Personalising treatment for myeloma patients based on initial response to NHS treatment and their overall fitness level
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN13185938·No longer recruiting·A study of JNJ-79635322 in participants with relapsed or refractory multiple myeloma or previously treated amyloid light-chain (AL) amyloidosis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17973108·No longer recruiting·Frailty-adjusted therapy in transplant non-eligible patients with newly diagnosed multiple myeloma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN46841867·No longer recruiting·A phase II and phase III trial comparing treatment escalation and de-escalation strategies in newly diagnosed patients with multiple myeloma suitable for stem cell transplant
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15028850·No longer recruiting·A randomised phase II trial of selinexor with cyclophosphamide and prednisolone in relapsed or refractory multiple myeloma (RRMM) patients
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16847817·No longer recruiting·MUK Nine b: OPTIMUM
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN04804337·No longer recruiting·Phase I dose-escalation study of oral administration of S55746 in patients with B-Cell Non-Hodgkin Lymphoma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17354232·No longer recruiting·A phase II randomised trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs cyclophosphamide, velcade and dexamethasone (CVD) for first relapse or primary refractory multiple myeloma
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Primary plasmacytoma of the bone — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Primary plasmacytoma of the bone" OR "Primary plasmacytoma of bone"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Primary plasmacytoma of the bone" OR "Primary plasmacytoma of bone"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"plasmacytoma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T06:54:16.925Z